Advertisement


Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

2024 ASCO Annual Meeting

Advertisement

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The KEYNOTE study is actually the study that established first-line combination VEGF-TKI, lenvatinib, and PD-1 inhibitor, pembrolizumab, as a standard therapy in metastatic renal cell cancer. The study has met several endpoint, progression-free survival, overall survival, and response rate showing that the combination of pembrolizumab and lenvatinib is superior to sunitinib. And here, what we did during the 2024 ASCO, great meeting by the way, we looked at baseline PD-L1 expression by immunohistochemistry, specific gene alteration by interrogating whole exome, and gene expression pattern using RNA-Seq. We did not have samples on all the patient from the full analysis, but the large subset we had on had similar baseline characteristic as the whole cohort. What we concluded is the combination of lenvatinib and pembrolizumab does work irrespective of PD-L1 immunohistochemistry. It showed that it worked and had a longer progression-free survival and improved response rate over sunitinib regardless of specific kidney cancer driver gene alteration, and these driver gene alteration are essentially the top mutated gene in kidney cancer, VHL, PBRM1, [inaudible 00:01:37], BAP1, KDM5C, but the combination is superior to sunitinib irrespective. And finally, we did look at a specific molecular subtype and gene expression, but the gene expression where the past several years reported specific to renal cell or not, but we looked at specific signature for renal cell cancer, the clusters, and universally, it showed that pembrolizumab-lenvatinib does work irrespective of any molecular subtypes, whether it's the angiogenesis subtype, the immune proliferative, et cetera. We will continue trying to find biomarkers specific to one therapy, and despite that this is a bit on the negative side, I think it's important to show that what doesn't work as biomarker as important show what does work.

Related Videos

Colorectal Cancer

Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone

Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).

Multiple Myeloma

Paula Rodríguez-Otero, MD, PhD, and Amrita Y. Krishnan, MD, on Multiple Myeloma: Moving BCMA-Directed Therapies to Earlier Use

Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with functional high-risk multiple myeloma; and DREAMM-7 on belantamab mafodotin-blmf plus bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory disease.

Skin Cancer

Pauline Funchain, MD and Paolo A. Ascierto, MD, on Advanced Melanoma: Results From the RELATIVITY-048 Trial

Pauline Funchain, MD, of Stanford University and the Stanford Cancer Institute, and Paolo A. Ascierto, MD, of Italy’s Istituto Nazionale Tumori and IRCCS Fondazione G. Pascale, discuss efficacy and safety findings of the triplet therapy nivolumab, relatlimab-rmbw, and ipilimumab in patients with advanced melanoma (Abstract 9504).

 

Multiple Myeloma

Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel

Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).

Prostate Cancer

Alicia Morgans, MD, MPH, and Karim Fizazi, MD, PhD, on Prostate Cancer: Study Findings on Health-Related Quality of Life and Pain

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).

Advertisement

Advertisement




Advertisement